Young-age prostate cancer

Hussein, Sundus; Satturwar, Swati; Kwast, Theodorus H. van der

doi:10.1136/jclinpath-2015-202993

Cited by 56 publications

(84 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Puerto Rican population being older than 60 years old is a risk factor for PCa as reported by Soto-Salgado et al [52]. Besides that, there have been reports (Hussein et al) that show that PCa may appear early in life (≤ 55 years old) [53], and that this early PCa onset may be associated and promoted by several genes [54]. Furthermore, these researchers state that PCa may remain undetectable in its early stages for many years until different factors like obesity, propitiate its development to a more aggressive stage [49,53,54].…”

Section: Discussionmentioning

confidence: 95%

“…Besides that, there have been reports (Hussein et al) that show that PCa may appear early in life (≤ 55 years old) [53], and that this early PCa onset may be associated and promoted by several genes [54]. Furthermore, these researchers state that PCa may remain undetectable in its early stages for many years until different factors like obesity, propitiate its development to a more aggressive stage [49,53,54]. In our cohort, the mean age at PCa diagnosis was 58 years old, particularly in the overweight group, which could suggest an agreement with Hussein [53].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, these researchers state that PCa may remain undetectable in its early stages for many years until different factors like obesity, propitiate its development to a more aggressive stage [49,53,54]. In our cohort, the mean age at PCa diagnosis was 58 years old, particularly in the overweight group, which could suggest an agreement with Hussein [53]. We cannot conclude that FTO is responsible for PCa development at early age in PR, but the poor dietary patterns in this population [29,34,55] may influence the FTO effect on obesity and hence in PCa.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of FTO SNPs rs9930506 and rs9939609 in Prostate Cancer Severity in a Cohort of Puerto Rican Men

Salgado-Montilla

Rodríguez-Cabán

Sánchez-García

et al. 2017

Can Res

View full text Add to dashboard Cite

Background Obesity is prevalent in PR and has been associated with prostate cancer (PCa) mortality and aggressiveness. Polymorphisms (SNPs) rs9930506 and rs9939609 in the FTO gene have been associated with both obesity and PCa. The aim of this work was to ascertain whether the presence of these SNPs is associated with PCa risk and severity in a cohort of Puerto Rican men. Methods and findings The study population consisted of 513 Puerto Rican men age ranging from 40–79 years old who underwent radical prostatectomy (RP) as the first treatment for PCa and 128 healthy Puerto Rican men age ranging from 40–79 years old. Genomic DNA (gDNA) was extracted and SNPs were determined by Real-Time PCR. PCa severity was defined based on RP stage and Gleason Score. The relationship of FTO SNPs with demographic, clinical characteristics, PCa status and PCa severity were assessed. Logistic regression models with a 95% confidence interval (CI) determined SNPs interaction with PCa risk and severity odds ratio (ORs). Results and discussion BMI, age and PSA were considered as confounders. Hardy-Weinberg equilibrium was present for both SNPs. The heterozygous forms (A/G; T/A) were the most prevalent genotypes and the frequency of alleles and genotypes for both SNPs agreed with those published in 1000 genomes. Results suggest an inverse association between the mutated rs9939609 and the risk of having PCa (OR: 0.53, 95% CI: 0.31–0.92) and a positive association with overweight (OR: 1.05, 95% CI: 0.68–1.62). Importantly, among the cases that were overweight, those with mutated rs9939609 had a greater chance of high severity PCa (OR: 1.39, 95% CI: 0.84–2.32) although these results were not statistical significant upon adjustment. Limitations of the study were the relatively small cohort and lack of access to the weight history of all our subjects. Conclusion Results offer a research line to be followed with an expanded number of subjects that may provide a better statistical significance, to unravel the high mortality rate in this population.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of FTO SNPs rs9930506 and rs9939609 in Prostate Cancer Severity in a Cohort of Puerto Rican Men

Salgado-Montilla

Rodríguez-Cabán

Sánchez-García

et al. 2017

Can Res

View full text Add to dashboard Cite

show abstract

“…In their review of young-age prostate cancer, Hussein et al noticed that young-age PCa has several biological and genetic features that are distinct from elderly-onset cancer, but in the majority of cases young men tend to have low grade and stage disease. On the other hand, the authors pay attention that early-onset PCa could represent a subset of young-age and familial PCa with more aggressive disease and higher prostate-cancer-specific death rate [6]. Until now, only two factors (family history and race) are confirmed to have close relationship with the detection of PCa in young men [21, 22], but the data about its aggressiveness is controversial.…”

Section: Discussionmentioning

confidence: 99%

“…The prevalence of latent PCa in younger men varies markedly among different autopsy series from 2.6% in Greek series [3] to a much higher 27% prevalence in Hungary [4] and up to 34% in USA [5]. Altogether, the study shows that about 20%–30% of 40–50-year-old men would harbor a PCa [6]. The increase of PCa diagnosis at young age raises a number of important questions about their biology and treatment modalities.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer

Milonas

Venclovas

Gudinavičienė

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Aim. The aim of this study was to describe PCa characteristics and long-term outcomes in young men aged ≤55 years after radical prostatectomy (RP) and to compare them with older men cohort. Methods. Among 2,200 patients who underwent RP for clinically localized PCa at our centre between 2001 and 2015, 277 (10.3%) men aged ≤55 years were identified. All preoperative and pathological parameters were compared between groups. Biochemical progression free survival (BPFS) and disease progression free survival (DPFS) were assessed at 5 and 10 years. Results. Men aged ≤55 years had similar pathological tumor characteristics and biochemical recurrence rate (BCR) compared to their older counterparts. Disease progression rate 2.5% versus 0.4% was higher in older patients (p = 0.026). BPFS rate was not different in both study groups. Estimated 10-year DPFS was 98.8% in younger men compared to 89.2% in their older counterparts (p = 0.031). Multivariate Cox regression showed that Gleason score lymph-nodes and surgical margins status were significant predictors for disease progression. Conclusions. In our cohort, men aged ≤55 years had similar pathological PCa characteristics and BCR rate in comparison with older men. RP can be performed with excellent long-term DPFS results in men with localized PCa at ≤55 years of age.

show abstract

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis

Zheng

Lin

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Objectives With the rapid increase in younger age prostate cancer (PCa) patients, the impact of younger age on decision‐making for PCa treatment needs to be revaluated in the new era. Materials and Methods A systematic literature search was performed using PubMed, EMBASE, and Web of Science up to October 2019 to identify the eligible radical prostatectomy (RP) studies focusing on understanding the impact of age on clinicopathological features and oncological prognosis in patients with localized PCa in PSA era. Meta‐analyses were conducted using available hazard ratios (HRs) from both univariate and multivariate analyses. Results Twenty‐six studies including 391 068 patients with RP treatments from the PSA era were included. Of these studies, age of 50 years old (age50) is the most commonly used cut‐off age to separate the younger patient group (including either age < 50 or age ≤ 50) from the older patient group. In these studies, the incidence of younger patients varied between 2.6% and 16.6% with a median of 8.3%. Younger patients consistently showed more favorable clinicopathological features correlated with better BCR prognosis. Meta‐analyses showed a 1.38‐fold improved BCR survival of younger patients in multivariate analysis. Among the high‐risk PCa patients, younger age was independently associated with worse oncological outcomes in multivariate analyses. Conclusion In this study, we found younger age correlated with favorable clinicopathological characteristics and better BCR prognosis in low‐ to intermediate‐risk patients. In high‐risk group patients, younger patients often showed significantly worse oncological outcomes. Our study results suggest that age 50 could be used as a practical cut‐off age to separate younger age patients from older age PCa patients.

show abstract

Young-age prostate cancer

Cited by 56 publications

References 48 publications

Impact of FTO SNPs rs9930506 and rs9939609 in Prostate Cancer Severity in a Cohort of Puerto Rican Men

Impact of FTO SNPs rs9930506 and rs9939609 in Prostate Cancer Severity in a Cohort of Puerto Rican Men

Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis

Contact Info

Product

Resources

About